Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Total Debt (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Total Debt for 7 consecutive years, with $15.0 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Total Debt changed N/A year-over-year to $15.0 million, compared with a TTM value of $15.0 million through Mar 2025, changed N/A, and an annual FY2022 reading of $60.7 million, down 3.89% over the prior year.
  • Total Debt was $15.0 million for Q1 2025 at Arcturus Therapeutics Holdings, down from $20.0 million in the prior quarter.
  • Across five years, Total Debt topped out at $63.5 million in Q1 2022 and bottomed at $15.0 million in Q1 2025.
  • Average Total Debt over 4 years is $52.0 million, with a median of $60.2 million recorded in 2022.
  • The sharpest move saw Total Debt skyrocketed 318.07% in 2021, then plummeted 66.52% in 2023.
  • Year by year, Total Debt stood at $63.1 million in 2021, then dropped by 3.89% to $60.7 million in 2022, then plummeted by 67.03% to $20.0 million in 2023, then fell by 25.0% to $15.0 million in 2025.
  • Business Quant data shows Total Debt for ARCT at $15.0 million in Q1 2025, $20.0 million in Q3 2023, and $60.7 million in Q4 2022.